1. Medicine

SIRT2 inhibition protects against cardiac hypertrophy and ischemic injury

  1. Xiaoyan Yang
  2. Hsiang-Chun Chang
  3. Yuki Tatekoshi
  4. Amir Mahmoodzadeh
  5. Maryam Balibegloo
  6. Zeinab Najafi
  7. Rongxue Wu
  8. Chunlei Chen
  9. Tatsuya Sato
  10. Jason Shapiro
  11. Hossein Ardehali  Is a corresponding author
  1. Feinberg Cardiovascular and Renal Research Institute, Northwestern University School of Medicine, United States
https://doi.org/10.7554/eLife.85571
Share this article
Cite this article
  1. Xiaoyan Yang
  2. Hsiang-Chun Chang
  3. Yuki Tatekoshi
  4. Amir Mahmoodzadeh
  5. Maryam Balibegloo
  6. Zeinab Najafi
  7. Rongxue Wu
  8. Chunlei Chen
  9. Tatsuya Sato
  10. Jason Shapiro
  11. Hossein Ardehali
(2023)
SIRT2 inhibition protects against cardiac hypertrophy and ischemic injury
eLife 12:e85571.
https://doi.org/10.7554/eLife.85571
  2. Download BibTeX
  3. Download .RIS

Abstract

Sirtuins (SIRT) exhibit deacetylation or ADP-ribosyltransferase activity and regulate a wide range of cellular processes in the nucleus, mitochondria, and cytoplasm. The role of the only sirtuin that resides in the cytoplasm, SIRT2, in the development of ischemic injury and cardiac hypertrophy is not known. In this paper, we show that the hearts of mice with deletion of Sirt2 (Sirt2-/-) display improved cardiac function after ischemia-reperfusion (I/R) and pressure overload (PO), suggesting that SIRT2 exerts maladaptive effects in the heart in response to stress. Similar results were obtained in mice with cardiomyocyte-specific Sirt2 deletion. Mechanistic studies suggest that SIRT2 modulates cellular levels and activity of nuclear factor (erythroid-derived 2)-like 2 (NRF2), which results in reduced expression of antioxidant proteins. Deletion of Nrf2 in the hearts of Sirt2-/- mice reversed protection after PO. Finally, treatment of mouse hearts with a specific SIRT2 inhibitor reduced cardiac size and attenuates cardiac hypertrophy in response to PO. These data indicate that SIRT2 has detrimental effects in the heart and plays a role in cardiac response to injury and the progression of cardiac hypertrophy, which makes this protein a unique member of the SIRT family. Additionally, our studies provide a novel approach for treatment of cardiac hypertrophy and injury by targeting SIRT2 pharmacologically, providing a novel avenue for the treatment of these disorders.

Editor's evaluation

In this manuscript, the authors examine the role of Sirt2 on cardiac hypertrophy by using 2 in-vivo models- systemic KO of Sirt2 and cardiac specific KO of Sirt 2. They have shown that Sirt2 is important for development of heart failure and cardiac hypertrophy. Mechanistically, the authors show that Sirt2 regulates NRF2 and that deletion of Sirt2 is protective through stabilization and increased nuclear translocation of NRF2.

https://doi.org/10.7554/eLife.85571.sa0

Introduction

Sirtuin (SIRT) family of proteins comprise class III of histone deacetylases. SIRTs require NAD+ to carry out their enzymatic reaction, and have been implicated in a wide range of cellular processes including aging, apoptosis, response to stress and inflammation, control of energy efficiency, circadian clocks, and mitochondrial biogenesis (Baur et al., 2012; Preyat and Leo, 2013). In mammals, seven sirtuins (SIRT1-7) have been identified, which are categorized according to their subcellular localization to the nucleus (SIRT1, -6, and -7), mitochondria (SIRT3, -4, and -5), and cytoplasm (SIRT2). SIRT1–3 have a robust deacetylation activity, while SIRT4 is reported to display ADP-ribosyltransferase activity. SIRT5 may function as a protein desuccinylase and demalonylase, and SIRT6 and SIRT7 display weak deacetylase activity (Du et al., 2011; Haigis et al., 2006; Michishita et al., 2005; Pan et al., 2011).

A number of SIRTs have been studied in the heart (for review, please see Matsushima and Sadoshima, 2015). The effects of SIRT1 in the heart are complex. Sirt1 deletion protects against pressure overload (PO)-induced cardiac hypertrophy (Oka et al., 2011; Sundaresan et al., 2011); however, low-level overexpression of SIRT1 in the heart attenuates age-associated cardiac hypertrophy, fibrosis, and cardiac dysfunction, while high-level overexpression of SIRT1 increases these pathological effects (Alcendor et al., 2007). In the setting of ischemia-reperfusion (I/R), SIRT1 exerts protective effects: Sirt1 knockout (KO) in the heart increases I/R-induced injury, while its overexpression protects against I/R-induced injury (Hsu et al., 2010). Thus, it appears that the effects of SIRT1 on cardiac response to stress are dependent on its expression levels as well as the context of injury. SIRT3 has also been studied in the heart and shown to protect against both cardiac hypertrophy and I/R injury (Porter et al., 2014; Sundaresan et al., 2009), while SIRT6 KO mice exhibit cardiac hypertrophy (Sundaresan et al., 2012). Recent studies have assessed the role of SIRT2 in the heart. One study showed that deletion of Sirt2 reduces AMPK activation and increases age-related and angiotensin II-mediated cardiac hypertrophy (Tang et al., 2017), while another showed that advanced glycation end products and its receptor promote diabetic cardiomyopathy through suppression of SIRT2, however, KO mice were not used for these studies (Yuan et al., 2015). Another study showed that Sirt2 deficiency increases nuclear localization of NFATc2 and its transcription activity, and that NFAT inhibition rescues the cardiac dysfunction in mice with Sirt2 deletion (Sarikhani et al., 2018).

Nuclear factor (erythroid-derived 2)-like 2 (NRF2) is a transcription factor that activates a number of cytoprotective genes, including antioxidative enzymes (Tufekci et al., 2011). Under normal conditions, NRF2 resides in the cytoplasm, and is degraded primarily through its interaction with Keap1 (kelch-like ECH-associated protein 1), which also serves as a bridge between NRF2 and cullin 3-ubiquitination complex (Tufekci et al., 2011). Under oxidative stress, NRF2 escapes degradation, translocates into the nucleus, and binds to antioxidant response elements in the promoter of a number of genes (Kaspar et al., 2009). NRF2 acetylation is decreased with SIRT1 overexpression (Kawai et al., 2011); however, an association between SIRT1 and NRF2 has not been demonstrated, and the functional consequences of NRF2 deacetylation have not been studied. NRF2 KO mice developed cardiac hypertrophy and heart failure (HF) after trans-aortic constriction (TAC) (Li et al., 2009), indicating the NRF2 is protective against cardiac stress. We recently showed that SIRT2 mediates NRF2 deacetylation in the liver cells and its translocation in the nucleus to regulate antioxidant genes (Yang et al., 2017).

In this paper, we show that SIRT2 plays a detrimental role in the heart in response to injury, in contrast to a previously published report (Tang et al., 2017). Mechanistically, deletion of Sirt2 is protective through stabilization and increased nuclear translocation of NRF2, leading to increased expression of antioxidant genes. Finally and most importantly, we show that pharmacological inhibition of SIRT2 protects the heart against the development of cardiac hypertrophy, opening potential treatment for this disorder.

Results

SIRT2 is expressed in the heart and its levels are elevated in HF

We first showed that SIRT2 is expressed in the heart (Figure 1—figure supplement 1A) and in H9c2 cardiomyoblasts (Figure 1—figure supplement 1B) at relatively high levels. We also found that SIRT2 expression was higher in the hearts of mice 4 weeks after TAC compared to sham (Figure 1A), while the levels of other sirtuin family members with major deacetylation activity that have been studied in the heart (i.e., SIRT1, SIRT3, and SIRT6) were not different. Additionally, we noted a significant increase in the levels of SIRT2 in the explanted hearts from end-stage HF patients with dilated cardiomyopathy (Figure 1B). We also assessed the levels of SIRT2 in explanted hearts from patients with ischemic cardiomyopathy and showed that SIRT2 is increased in these hearts (Figure 1C). These results indicate that SIRT2 levels are increased in HF and ischemic injury.

Figure 1 with 1 supplement see all
Download asset Open asset
SIRT2 is upregulated in heart failure (HF).

(A) SIRT1, SIRT2, SIRT3, and SIRT6 in mouse hearts after trans-aortic constriction (TAC). (B) SIRT2 in human hearts from healthy patients and patients with dilated cardiomyopathy. (C) SIRT2 protein levels in the hearts of control individual and patients with ischemic heart failure. *p<0.05 by Student’s t-test. Data presented as mean ± SEM.

Figure 1—source data 1

SIRT1, -2, -3, and -6 after sham and trans-aortic constriction (TAC) surgery as shown in Figure 1A.

https://cdn.elifesciences.org/articles/85571/elife-85571-fig1-data1-v2.csv
Figure 1—source data 2

SIRT2 in non-failing and failing human hearts as shown in Figure 1B.

https://cdn.elifesciences.org/articles/85571/elife-85571-fig1-data2-v2.csv
Figure 1—source data 3

SIRT2 in non-failing and ischemic human hearts as shown in Figure 1C.

https://cdn.elifesciences.org/articles/85571/elife-85571-fig1-data3-v2.csv
Figure 1—source data 4

Full gels for Figure 1A–C.

https://cdn.elifesciences.org/articles/85571/elife-85571-fig1-data4-v2.pptx
Figure 1—source data 5

Full gels for Figure 1A–C unedited.

https://cdn.elifesciences.org/articles/85571/elife-85571-fig1-data5-v2.pptx
Figure 1—source data 6

Full gels for Figure 1A–C unedited.

https://cdn.elifesciences.org/articles/85571/elife-85571-fig1-data6-v2.zip

Sirt2 deficiency preserves cardiac function in response to PO and I/R injury

We first used mice with global deletion of Sirt2 KO (Sirt2-/-) for our studies. We assessed whether Sirt2 deletion affects the levels of other sirtuin family members in the heart. Sirt2-/- hearts displayed no change in other sirtuin family members at the mRNA level, and no change in protein levels of SIRT1, SIRT3, or SIRT6 (sirtuins with major deacetylation activity) was detected (Figure 2—figure supplement 1). We then assessed whether Sirt2 deletion protects against PO. Sirt2-/- mice displayed normal cardiovascular parameters at baseline and no overt phenotype. However, in response to TAC, Sirt2-/- mice displayed improved cardiac function than littermate controls, as assessed by fractional shortening (FS) and ejection fraction (EF) (Figure 2A and B). Additionally, Sirt2-/- mice displayed evidence of less cardiac hypertrophy, as evidenced by lower interventricular septal (IVS) thickness on echocardiography (Figure 2C), and reduced cardiac size and heart weight to body weight ratio on gross examination (Figure 2D and E). Histological examination of the hearts also showed smaller cardiomyocytes in Sirt2-/- hearts after PO, as assessed by H&E staining (Figure 2F and G). These data indicate that deletion of Sirt2 results in protection of the heart against PO with improved cardiac function and less cardiac hypertrophy.

Figure 2 with 1 supplement see all
Download asset Open asset
Sirt2 deficiency protects the heart against cardiac dysfunction after trans-aortic constriction (TAC).

Sirt2-/- and wild-type (WT) littermates were subjected to TAC and ejection fraction (EF) (A), fractional shortening (FS) (B), and interventricular septal thickness during diastole (C) were assessed 4 weeks later (N=6–9). (D–F) Representative hearts (D), HW/BW (E) (N=3–5), H&E staining, (F) and the summary of cross-sectional area of cardiomyocytes (G) in WT and Sirt2-/- hearts (N=20 cardiomyocytes), *p<0.05 by one-way ANOVA and post hoc Tukey analysis (A, B, C, and E) and unpaired Student’s t-test (G). Bars represent group mean.

Figure 2—source data 1

Ejection fraction (EF) in wild-type (WT) and Sirt2-/- mice after sham or trans-aortic constriction (TAC) as shown in Figure 2A.

https://cdn.elifesciences.org/articles/85571/elife-85571-fig2-data1-v2.csv
Figure 2—source data 2

Fractional shortening (FS) in wild-type (WT) and Sirt2-/- mice after sham or trans-aortic constriction (TAC) as shown in Figure 2B.

https://cdn.elifesciences.org/articles/85571/elife-85571-fig2-data2-v2.csv
Figure 2—source data 3

Interventricular septal (IVS) thickness diastole in wild-type (WT) and Sirt2-/- mice after sham or trans-aortic constriction (TAC) as shown in Figure 2C.

https://cdn.elifesciences.org/articles/85571/elife-85571-fig2-data3-v2.csv
Figure 2—source data 4

HW/BW in wild-type (WT) and Sirt2-/- mice after sham or trans-aortic constriction (TAC) as shown in Figure 2E.

https://cdn.elifesciences.org/articles/85571/elife-85571-fig2-data4-v2.csv
Figure 2—source data 5

CSA in wild-type (WT) and Sirt2-/- hearts as shown in Figure 2G.

https://cdn.elifesciences.org/articles/85571/elife-85571-fig2-data5-v2.csv

To better assess the role of SIRT2 in the development of HF and ischemic damage, we then studied the effects of Sirt2 deletion in the heart on the response to I/R. We subjected Sirt2-/- and their littermate wild-type (WT) controls to I/R and cardiac function was assessed after 7 and 21 days. At both time points, EF and FS were significantly higher in Sirt2-/- mice compared to controls (Figure 3A and B). Time course of cardiac assessment showed that while FS was comparable between WT and Sirt2-/- on day 3, it quickly deteriorated in WT mice, consistent with transition into HF, while Sirt2-/- mice maintained their cardiac function (Figure 3C). To further support these findings, we assessed the effects of Sirt2 modulation on cell death in response to H2O2 in neonatal rat cardiomyocytes (NRCMs) treated with control or Sirt2 siRNA by measuring propidium iodide (PI) positive cells. We found that cells with Sirt2 knockdown (KD) displayed improved cell viability in response to H2O2 (Figure 3D and E). Overall, these results indicate that SIRT2 exerts detrimental effects in the heart in response to PO and I/R, and that its deletion leads to protective effects.

Figure 3
Download asset Open asset
Hearts from Sirt2-/- mice are protected against ischemia-reperfusion (I/R) injury.

Ejection fraction (EF) and fractional shortening (FS) in wild-type (WT) and Sirt2-/- mice 7 (A) and 21 days (B) after I/R (N=4–5). (C) Time course of FS in Sirt2-/- mice after I/R injury (N=4–5). (D, E) Cell death assessed by propidium iodide (PI), in neonatal rat cardiomyocyte (NRCM) treated with control or Sirt2 siRNA and with 500 µM of H2O2. *p<0.05 by ANOVA for all panels expect for panel C, where Student’s t-test was used for comparison between the two time points. Bars represent mean (A, B), and data presented as mean ± SEM.

Figure 3—source data 1

Ejection fraction (EF) and fractional shortening (FS) in wild-type (WT) and Sirt2-/- mice after ischemia-reperfusion (I/R) as shown in Figure 3A.

https://cdn.elifesciences.org/articles/85571/elife-85571-fig3-data1-v2.csv
Figure 3—source data 2

Ejection fraction (EF) and fractional shortening (FS) in wild-type (WT) and Sirt2-/- mice after ischemia-reperfusion (I/R) as shown in Figure 3B.

https://cdn.elifesciences.org/articles/85571/elife-85571-fig3-data2-v2.csv
Figure 3—source data 3

Time course of fractional shortening (FS) in wild-type (WT) and Sirt2-/- mice after ischemia-reperfusion (I/R) as shown in Figure 3C.

https://cdn.elifesciences.org/articles/85571/elife-85571-fig3-data3-v2.csv
Figure 3—source data 4

Propidium iodide (PI) positive cells as shown in Figure 3E.

https://cdn.elifesciences.org/articles/85571/elife-85571-fig3-data4-v2.csv

The experiments in Figures 2 and 3 were conducted in mice with global deletion of Sirt2. To confirm a role for SIRT2 in cardiomyocyte response to injury, we then generated cardiac-specific Sirt2 KO mice (cs-Sirt2-/-) by crossing Sirt2 floxed mice with αMHC-Cre mice. We confirmed lack of SIRT2 expression and no change in SIRT1 and SIRT3 in the hearts of cs-Sirt2-/- mice (Figure 4—figure supplement 1). The cs-Sirt2-/- mice were then subjected to TAC with littermate Cre negative mice as control, and cardiac functions (EF and FS) were assessed at 1 and 2 weeks after injury. At both time points, cs-Sirt2-/- mice displayed improved cardiac function compared to WT controls (Figure 4A and B). Consistent with these data, HF markers in the heart, including Nppa and Nppb, were significantly lower in cs-Sirt2-/- mice after TAC (Figure 4C and D). To determine whether these effects are gender specific, we also preformed TAC in female Sirt2f/f and cs-Sirt2-/- mice and demonstrated that they are also protected against TAC at 7 and 14 days (Figure 4—figure supplement 2). Finally, the hearts of cs-Sirt2-/- mice are also protected against I/R, as their function was significantly higher (Figure 4E) and degree of ischemic damage was lower (Figure 4F) than Sirt2f/f mice 14 days after I/R.

Figure 4 with 2 supplements see all
Download asset Open asset
cs-Sirt2-/- hearts are protected against trans-aortic constriction (TAC) and ischemia-reperfusion (I/R).

Ejection fraction (EF) and fractional shortening (FS) in Sirt2f/f and cs-Sirt2-/- mice 7 (A) and 14 days (B) after TAC (N=5–9). (C,D) mRNA levels of Anf (C) and Bnp (D) in the hearts of Sirt2f/f and cs-Sirt2-/- mice 4 weeks after TAC (N=7–8). (E) EF and FS in Sirt2f/f and cs-Sirt2-/- mice 7 and 14 days after I/R (N=4). (F) Necrotic area (representing the degree of ischemic damage) in Sirt2f/f and cs-Sirt2-/- mice 14 days after MI. *p<0.05 by ANOVA for panels A and B, and Student’s t-test was used for panels C and D. Data are presented as mean ± SEM.

Figure 4—source data 1

Ejection fraction (EF) and fractional shortening (FS) in Sirt2f/f and cs-Sirt2-/- mice 7 days after ischemia-reperfusion (I/R) as shown in Figure 4A.

https://cdn.elifesciences.org/articles/85571/elife-85571-fig4-data1-v2.csv
Figure 4—source data 2

Ejection fraction (EF) and fractional shortening (FS) in Sirt2f/f and cs-Sirt2-/- mice 14 days after ischemia-reperfusion (I/R) as shown in Figure 4B.

https://cdn.elifesciences.org/articles/85571/elife-85571-fig4-data2-v2.csv
Figure 4—source data 3

Nppa mRNA in Sirt2f/f and cs-Sirt2-/- hearts as shown in Figure 4C.

https://cdn.elifesciences.org/articles/85571/elife-85571-fig4-data3-v2.csv
Figure 4—source data 4

Nppb mRNA in Sirt2f/f and cs-Sirt2-/- hearts as shown in Figure 4D.

https://cdn.elifesciences.org/articles/85571/elife-85571-fig4-data4-v2.csv
Figure 4—source data 5

Echo parameters in Sirt2f/f and cs-Sirt2-/- hearts as shown in Figure 4E.

https://cdn.elifesciences.org/articles/85571/elife-85571-fig4-data5-v2.xlsx

SIRT2 deacetylates NRF2 resulting in decreased transcriptional activity in the heart

We previously showed that SIRT2 deacetylates NRF2 protein in the liver and alters iron release from hepatocytes (Yang et al., 2017). Since deacetylation of NRF2 leads to protein destabilization and NRF2 regulates the expression of many antioxidant genes, we hypothesized that the mechanism for the protective effects of Sirt2 deletion in response to stress is through decreased NRF2 deacetylation and degradation, resulting in increased expression of antioxidant proteins. To test this hypothesis, we first assessed whether there is physical interaction between SIRT2 and NRF2 in the heart. Co-immunoprecipitation (IP) experiments showed that SIRT2 interacts with NRF2 in the heart of WT mice (Figure 5A).

Figure 5 with 3 supplements see all
Download asset Open asset
SIRT2 interacts with nuclear factor (erythroid-derived 2)-like 2 (NRF2) and regulates its activity in the heart.

(A) Co-immunoprecipitation (IP) of SIRT2 and NRF2 in extracts of hearts from wild-type (WT) mice. (B) Endogenous NRF2 acetylation levels in the hearts of WT and Sirt2-/- mice at the baseline. Acetylated proteins were IPed by anti-acetyl antibody followed by immunoblotting with anti-NRF2 antibody. (C) NRF2 protein levels in neonatal rat cardiomyocytes (NRCMs) treated with Sirt2 siRNA. (D) NRF2 protein levels in H9c2 cells treated with control or Sirt2 siRNA and harvested at different time points after treatment with 100 µg/ml of CHX. (E) NRF2 protein levels in the nucleus in NRCMs treated with control or Sirt2 siRNA. (F–H) mRNA levels of NRF2 target genes in pentose phosphate pathway (F), quinone and glutathione-based detoxification (G), thioredoxin production (H) in H9c2 cells overexpressing empty vector (white bars) or SIRT2 (gray bars). *p<0.05 by Student’s t-test.

Figure 5—source data 1

mRNA with overexpression of EV or SIRT2 as shown in Figure 5F.

https://cdn.elifesciences.org/articles/85571/elife-85571-fig5-data1-v2.csv
Figure 5—source data 2

mRNA with overexpression of EV or SIRT2 as shown in Figure 5G.

https://cdn.elifesciences.org/articles/85571/elife-85571-fig5-data2-v2.csv
Figure 5—source data 3

mRNA with overexpression of EV or SIRT2 as shown in Figure 5H.

https://cdn.elifesciences.org/articles/85571/elife-85571-fig5-data3-v2.csv
Figure 5—source data 4

Uncropped gels for Figure 5.

https://cdn.elifesciences.org/articles/85571/elife-85571-fig5-data4-v2.pptx
Figure 5—source data 5

Uncropped gels for Figure 5 unedited.

https://cdn.elifesciences.org/articles/85571/elife-85571-fig5-data5-v2.pptx
Figure 5—source data 6

Uncropped gels for Figure 5 unedited.

https://cdn.elifesciences.org/articles/85571/elife-85571-fig5-data6-v2.zip

We then measured acetylation levels of NRF2 in WT and Sirt2-/- hearts, and showed that NRF2 acetylation levels are increased within Sirt2-/- hearts (Figure 5B). We then assessed whether deacetylation of NRF2 alters its levels in the cardiac cells, as shown before in the liver (Yang et al., 2017). Treatment of NRCMs with Sirt2 siRNA resulted in increased NRF2 protein levels compared with control siRNA, indicating that SIRT2 leads to a reduction in the levels of NRF2 protein (Figure 5C). Since NRF2 protein levels are higher in Sirt2-/- hearts, we next assessed whether SIRT2 alters the stability of NRF2 protein. NRF2 levels were significantly lower starting at 60 min after treatment with the protein synthesis inhibitor cycloheximide (CHX), leading to almost complete degradation at 120 min in cells treated with control siRNA. However, we noted no change in NRF2 protein levels in cells treated with Sirt2 siRNA (Figure 5D). These data indicate that SIRT2 binds to NRF2, and its deacetylation leads to the instability and degradation of NRF2.

NRF2 is a transcription factor and upon activation, translocates into the nucleus to exert its transcriptional activity (Hybertson et al., 2011). Thus, we measured nuclear level of NRF2 and found it to be increased in NRCMs with Sirt2 KD (Figure 5E). Since the increase in nuclear levels of NRF2 suggests possibly higher transcriptional activity of the protein, we next assessed the effects of Sirt2 modulation on NRF2 transcriptional activity in H9c2 cells treated with lentivirus expressing either control or SIRT2 lentivirus. Consistent with its increased nuclear levels, SIRT2 overexpression in H9c2 cells resulted in lower levels of known NRF2 target genes (Figure 5F–H). However, the mRNA levels of non-NRF2 targeted antioxidant genes were not affected by SIRT2 overexpression (Figure 5—figure supplement 1). We confirmed the data in mouse HL-1 atrial cell line and showed an increase in NRF2 protein with Sirt2 KD and a decrease in NRF2 target proteins with overexpression of SIRT2 (Figure 5—figure supplement 2).

Since our data suggest a role for SIRT2 in the regulation of NRF2-mediated expression of antioxidant genes, we next assessed whether SIRT2 has an effect on reactive oxygen species (ROS) production. NRCMs treated with Sirt2 siRNA displayed less ROS levels after treatment with H2O2 (Figure 5—figure supplement 3), further supporting a role for SIRT2 in regulating oxidative state of cardiomyocytes.

Sirt2/Nrf2 double KO mice display more cardiac damage after I/R compared to Sirt2-/- mice

Our results thus far demonstrate that NRF2 is a target of SIRT2 and that SIRT2 regulates NRF2 acetylation and protein levels. To determine whether the protective effects of SIRT2 are mediated through NRF2, we generated Sirt2/Nrf2 double KO mice and subjected the mice to I/R injury. The Sirt2/Nrf2 double KO mice displayed reduced EF and FS compared to Sirt2-/- mice (Figure 6A and B), indicating that deletion of Nrf2 reverses the protective effects of SIRT2.

Figure 6
Download asset Open asset
Nrf2 deletion and SIRT2 inhibitors protected against cardiac damage and cardiac hypertrophy.

Ejection fraction (EF) (A) and fractional shortening (FS) (B) in wild-type (WT), Sirt2-/-, and Sirt2-/-/Nrf2-/- double knockout (KO) mice 28 days after ischemia-reperfusion (I/R) (N=4–5). (C) Protocol for treatment of mice with SIRT2 inhibitor, AGK2. (D) Echo images of hearts from WT mice treated with either vehicle or AGK2. (E–J) EF (E), FS (F), left ventricular diameter during diastole (LVDd) (G), left ventricular diameter during systole (LVDs) (H), IVSd (I), and posterior wall thickness during diastole (PWTd) (J) in WT mice treated with AGK after trans-aortic constriction (TAC) according to the protocol in panel C (N=6–10). *p<0.05 by ANOVA for panels A–B or Student’s t-test for panels E–J.

Figure 6—source data 1

Ejection fraction (EF) in wild-type (WT), Sirt2-/-, and Sirt2-/-/Nrf2-/- mice after ischemia-reperfusion (I/R) as shown in Figure 6A.

https://cdn.elifesciences.org/articles/85571/elife-85571-fig6-data1-v2.csv
Figure 6—source data 2

Fractional shortening (FS) in wild-type (WT), Sirt2-/-, and Sirt2-/-/Nrf2-/- mice after ischemia-reperfusion (I/R) as shown in Figure 6B.

https://cdn.elifesciences.org/articles/85571/elife-85571-fig6-data2-v2.csv
Figure 6—source data 3

Ejection fraction (EF) with AGK2 as shown in Figure 6E.

https://cdn.elifesciences.org/articles/85571/elife-85571-fig6-data3-v2.csv
Figure 6—source data 4

Fractional shortening (FS) with AGK2 as shown in Figure 6F.

https://cdn.elifesciences.org/articles/85571/elife-85571-fig6-data4-v2.csv
Figure 6—source data 5

Left ventricular diameter during diastole (LVDd) with AGK2 as shown in Figure 6G.

https://cdn.elifesciences.org/articles/85571/elife-85571-fig6-data5-v2.csv
Figure 6—source data 6

LVDs with AGK2 as shown in Figure 6H.

https://cdn.elifesciences.org/articles/85571/elife-85571-fig6-data6-v2.csv
Figure 6—source data 7

IVSd with AGK2 as shown in Figure 6I.

https://cdn.elifesciences.org/articles/85571/elife-85571-fig6-data7-v2.csv
Figure 6—source data 8

Posterior wall thickness during diastole (PWTd) with AGK2 as shown in Figure 6J.

https://cdn.elifesciences.org/articles/85571/elife-85571-fig6-data8-v2.csv

Pharmacological inhibition of SIRT2 protects the heart against ischemic damage

Since a reduction in SIRT2 levels led to protection against the development of HF and cardiac hypertrophy, we next studied whether pharmacological inhibition of SIRT2 also exerts protective effects in the heart in response to PO. For these studies, we used AGK2, a selective SIRT2 inhibitor (He et al., 2012; Outeiro et al., 2007; Petrilli et al., 2013). Eight-week-old C57B6 mice were underwent TAC and 1 day later, they were randomized to treatment with 40 mg/kg of AGK2 or vehicle intraperitoneally twice a week for 4 weeks. At the conclusion of the study, their cardiac function and heart chamber size were assessed using echocardiography (Figure 6C). Treatment with AGK2 did not change the systolic function of the heart, as assessed by EF, FS (Figure 6D–F). However, measures of cardiac size, as assessed by left ventricular (LV) diameter during diastole and systole (LVDd and LVDs, respectively), were increased, while measures of LV wall diameter, as assessed by IVSd and posterior wall thickness during diastole (PWTd), were reduced (Figure 6G–J). These results indicate that pharmacological inhibition of SIRT2 can protect the heart against cardiac hypertrophy and improve cardiac remodeling in response to PO.

Discussion

Sirtuins play a major role in post-translational modification of proteins, and their deletion have been shown to lead to a number of physiological changes and pathological conditions (Baur et al., 2012; Watroba and Szukiewicz, 2021; Zhao et al., 2020). Although multiple sirtuins have been investigated in the context of cardiovascular diseases (Tang et al., 2017; Yuan et al., 2015; Sarikhani et al., 2018), it is not known whether SIRT2 has a role in protection against HF and cardiac hypertrophy. In this paper, we used genetic models to show that SIRT2 has detrimental effects in the heart in the setting of cardiac insults and demonstrate that the deleterious effects of SIRT2 is through increased NRF2 deacetylation and its degradation and eventual reduction in the levels of antioxidant genes. We also show that deletion of Nrf2 reverses the protective effects of Sirt2 deletion. Finally, we provide a clinical significance for our findings and show that treatment of mice with AGK2, a selective SIRT2 inhibitor, results in protection against cardiac hypertrophy in response to PO.

NRF2 plays a major role in the regulation of genes involved in oxidative stress, metabolic processes, drug metabolism, and stress response, among others. Thus, its activation has been studied extensively in a number of diseases, however, these studies have not led to an effective therapy. It is possible that direct activation of NRF2 may have unwanted side effects. Our studies provide a proof of concept that targeting SIRT2 and indirect activation of NRF2 by altering its post-translational protein modification may prove to be a more effective therapeutic strategy for a number of diseases.

Cardiac hypertrophy is a major complication of hypertrophy and metabolic disorders in this country (Husser et al., 2018; Moon et al., 2020; Semsarian et al., 2015), however, our treatment options are limited. We generally treat the underlying cause without directly targeting cardiac function and remodeling. Our data indicate that targeting SIRT2 with AGK2 would improve cardiac remodeling and cardiac hypertrophy in response to PO, potentially providing a novel therapy for these disorders. However, systemic inhibition of SIRT2 may have unwanted side effects, which would need to be investigated further.

A few limitations should be taken into consideration regarding our findings. First, as global Nrf2 KO mice were used in this study, we cannot rule out possible role of Nrf2 deletion in non-cardiac tissues in reversing the effects of Sirt2 deletion. Additionally, the systemic and cardiac-independent effects of AGK drug cannot be ruled out in our studies. Finally, our data are not consistent with two previous studies that have shown protective effects of SIRT2 in the heart, with one study showing that deletion of Sirt2 increases age-related and angiotensin II-mediated cardiac hypertrophy (Tang et al., 2017), while another study showing that Sirt2 deficiency leads to cardiac dysfunction and cardiac hypertrophy (Sarikhani et al., 2018). The reason for this discrepancy in our data is not clear, however, we used both global and cardiac specific KO of Sirt2, while these studies have used mice with global deletion of the gene. The genetic background of the mice and the different gene targeting strategy might have also contributed to the difference. Additionally, these studies used either angiotensin- or isoproterenol-induced models to cause cardiac hypertrophy and other potential effects of these drugs may explain the differences in our results. However, we used two different genetic models (global and cardiac specific KO of Sirt2) and a pharmacological approach to test our hypothesis, all of which produced similar results. Finally, we provide a mechanism for the deleterious effects of SIRT2 in the heart through its regulation of antioxidant proteins by NRF2 protein.

In summary, our data demonstrate that SIRT2 has deleterious effects in the heart through its post-translational modification of NRF2. We show that SIRT2 binds to NRF2 and that Sirt2 deletion leads to an increase in NRF2 stability and nuclear levels, resulting in higher production of antioxidant genes. Additionally, deletion of Nrf2 reverses the protective effects of Sirt2 deletion. Finally, our results provide a potential therapy for cardiac hypertrophy by using AGK2, a specific inhibitor of SIRT2.

Materials and methods

Animal models

Request a detailed protocol

All animals were maintained and handled in accordance with the Northwestern Animal Care and Use Committee. Sirt2-/- and Sirt2 floxed mice were obtained from Dr. David Gius. Nrf2-/- mice were purchased from Jackson labs. Sirt2-/-/Nrf2-/- mice were generated by crossing the Sirt2-/- with Nrf2-/- mice. All animals were kept in accordance with standard animal care requirements and maintained in a 22°C room with a 12 hr light/dark cycle, and received food and drinking water ad libitum.

Study approval

Request a detailed protocol

All animal studies were approved by the Institutional Animal Care and Use Committee at Northwestern University (Chicago, IL, USA) and were performed in accordance with the guidelines from the National Institutes of Health. The approval number of the animal protocol currently associated with this activity is IS00006808.

Human heart samples

Request a detailed protocol

Non-failing and cardiomyopathy cardiac tissue samples were obtained from the Human Heart Tissue Collection at the Cleveland Clinic. Informed consent was obtained from all the transplant patients and from the families of the organ donors before tissue collection. Protocols for tissue procurement were approved by the Institutional Review Board of the Cleveland Clinic (Cleveland, OH, USA), which is AAHRPP accredited. The experiments conformed to the principles set out in the WMA Declaration of Helsinki and the Department of Health and Human Services Belmont Report.

Animal surgeries

Request a detailed protocol

Cardiac surgeries were performed as previously described (Wu et al., 2011; Wu et al., 2012). Briefly, mice of 10–12 weeks of age were anesthetized with 2% isoflurane. The animals were placed in a supine position and ECG leads were attached. The body temperature was monitored using a rectal probe and was maintained at 37°C with heating pads throughout the experiment. A catheter was inserted into the trachea and was then attached to the mouse ventilator via a Y-shaped connector. The mice were ventilated at a tidal volume of 200 μl and a rate of 105 breaths/min using a rodent ventilator. Chronic PO was induced by TAC as described. A 7-0 silk suture was placed around the transverse aorta between the origin of the right innominate and left common carotid arteries against an externally positioned 27-gauge needle to yield a narrowing 0.4 mm in diameter when the needle was removed after ligation. The sham procedure was identical except that the aorta was not ligated. For cardiac I/R injury, a 1 mm section of PE-10 tubing was placed on top of left anterior descending artery, and a knot was tied on the top of the tubing to occlude the coronary artery with an 8-0 silk suture. Ischemia was verified by pallor of the anterior wall of the left ventricle and by ST-segment elevation and QRS widening on the ECG. After occlusion for 45 min, reperfusion occurred by cutting the knot on top of the PE-10 tubing. Animals were given buprenorphine for post-operative pain.

Echocardiography

Request a detailed protocol

Parasternal short- and long-axis views of the heart were obtained using a Vevo 770 high-resolution imaging system with a 30 MHz scan head. 2D and M-mode images were obtained and analyzed. EF was calculated from M-mode image using Teichholtz equation, and FS was directly calculated from end-systolic and end-diastolic chamber size from M-mode images.

Histological analysis

Request a detailed protocol

Hearts were fixed in 10% formalin (PBS buffered), dehydrated, and embedded in paraffin. Heart architecture was determined from transverse 5 μm deparaffinized sections stained with H&E. Fibrosis was detected with Masson’s trichrome staining.

Cell culture and reagents

Request a detailed protocol

NRCMs were isolated from 1- to 2-day-old Sprague-Dawley rats as previously described (Ichikawa et al., 2012). Cardiomyocytes were cultured in DMEM, supplemented with 5% FBS, 1.5  mM vitamin B12, and 1 mM penicillin-streptomycin (Gibco). To prevent proliferation of non-myocytes, 100 µM bromodeoxyuridine was added to the culture media. To induce oxidative stress, cells were exposed to hydrogen peroxide (H2O2, VWR) for 4 hr. CHX (Sigma) was used to check protein stability. H9c2 line were grown on DMEM, supplemented with 10% FBS. All cells were maintained in a 37°C incubator with 5% CO2 and 6% oxygen and were 70–90% confluent when collected for various analyses unless otherwise noted. HL1 cells were cultured in Claycomb media (Sigma-Aldrich) containing 10% serum, 0.1 mM norepinephrine, 2 mM L-glutamine, and penicillin/streptomycin, as previously described (Rines et al., 2017). H9c2 cells were obtained from ATCC and were grown in Dulbecco’s Modified Eagle’s Medium (Corning) supplemented with 10% FBS (Atlanta Biologicals), as described previously (Sato et al., 2018). We routinely check for mycoplasma in our lab.

Plasmids and transfections

Request a detailed protocol

pcDNA vector containing SIRT2 and corresponding empty vector were gifts from Dr. David Guis. Sirt2 siRNA were purchased from Dharmacon. For plasmid and siRNA transient transfection, cells were transfected using Lipofectamine 2000 Transfection Reagent (Invitrogen, Thermo Fisher Scientific) and Dharmafect transfection reagent (Horizon) according to the manufacturer’s instructions.

Protein stability assay

Request a detailed protocol

For protein stability studies, 100 μg/ml of CHX (Sigma) was added to H9c2 cells, and samples were isolated at 0, 15, 30, 60, 90, and 120 min after the addition of CHX. Samples were then run on a gel for western blot analysis.

RNA isolation and qRT-PCR

Request a detailed protocol

RNA was isolated using RNA-STAT60 (Tel-Test) according to the manufacturer’s instructions and subjected to DNAse I (Ambion) digestion to remove residual DNA. Purified RNA was then reverse transcribed with random hexamer and oligo-dT (Yuan et al., 2015) (Applied Biosystems) and amplified on a 7500 Fast Real-Time PCR system using Fast SYBR Green PCR Master Mix (Applied Biosystems). The sequences for primers are included in Appendix 1—table 1. mRNA levels were calculated based on the difference of threshold Ct values in the target gene and average Ct values of 18s, Actb, B2m, and Hprt in the same sample.

Cell death studies

Request a detailed protocol

Permeability to PI (Sigma-Aldrich) was used as a fluorescent signal for cell death (Ardehali et al., 2005). NRCMs were treated with H2O2 for 4 hr, washed one time with HBSS and co-stained with PI and Hoescht. After several steps of wash, images were taken using Zeiss AxioObserver.Z1 fluorescent microscope. Data were analyzed with ImageJ (NIH).

Measurement of ROS

Request a detailed protocol

Intracellular ROS levels were determined using dihydroethidium (DHE) assay. Briefly, NRCMs were treated with H2O2. After 4 hr of incubation, cells were washed and loaded with 10 µM DHE and Hoechst for 30 min. After two washing steps, fluorescence images were acquired with the Zeiss AxioObserver.Z1.

Isolation of nuclei

Request a detailed protocol

Nuclei were isolated using NE-PER Nuclear and Cytoplasmic Extraction Reagents (Pierce).

Western blot and IP

Request a detailed protocol

20–40 µg of protein were resolved on SDS-PAGE gels and transferred to nitrocellulose membranes (Invitrogen, CA, USA). The membranes were probed with antibodies against SIRT1, SIRT2 (Sigma-Aldrich), SIRT3, SIRT6 (Cell Signaling Technology), NRF2 (Abcam, cell signaling), HPRT, GAPDH (Proteintech), TBP, and β-actin (Abcam). HRP-conjugated donkey anti-rabbit and donkey anti-mouse were used as secondary antibodies (Jackson ImmunoResearch) and visualized by Pierce Super Signal Chemiluminescent Substrates.

For IP, cells or tissue were lysed using IP buffer (25 mM Tris-HCl pH 7.5, 150 mM NaCl, 1 mM EDTA, 0.1% NP-40, and 5% glycerol), and cell extracts were incubated overnight with appropriate antibodies followed by incubation with protein A or G agarose beads for 4 hr at 4°C. After washing five times with IP buffer, immunocomplexes were resolved using SDS-PAGE and analyzed by western blot.

Treatment of WT mice with AGK2

Request a detailed protocol

AGK2 administration to C57BL6J mice which underwent TAC surgery by intraperitoneal injection was started 1 day after the surgery with the dose of 40 mg/kg. The injection was performed twice a week for 4 weeks, and then their cardiac function was assessed by echocardiography.

AGK2 (Selleckchem) was dissolved in DMSO, and administered to C57BL6-J mice 2 hr before TAC surgery and then twice a week at a dose of 40 mg/kg started on day 1 after the surgery and continued for 2 weeks. At the end of studies, cardiac function was assessed by echocardiography.

Statistical analysis

Request a detailed protocol

For sample size, based on our previous experience with similar studies, we estimated at least four to six animals per group are needed to detect significant functional difference. However, the sample size was not pre-determined. Animals were randomized into sham versus control group. Surgical operator was blinded regarding animal’s genotype. For AGK2 treatment study, mice were randomized into control versus AGK2 group. Data analysis was not masked. The replicate number for in vitro experiment and animal numbers for in vivo experiments were based on our prior experience of studying gene expression and cardiac function after insult. All reported replicates for in vitro experiments are technical replicates (unless otherwise specifically noted).

All data are expressed as mean ± SEM. Exclusion criteria were not pre-established. No sample or data points were omitted from analysis. Statistical significance was assessed with two-tailed unpaired t-test for two group comparison or with ANOVA for data with more than two groups. Post hoc Tukey’s test was performed for multiple-group comparison if ANOVA reached statistical significance. Kolmogorov-Smirnov test was used to test for normal distribution. Levene’s test was used to evaluate equal variance among groups. A p-value of <0.05 was considered statistically significant.

Appendix 1

Appendix 1—table 1
Primer sequences.
GenesForward primerReverse primerSpecies
NppaGGGTAGGATTGACAGGATTGGCCTCCTTGGCTGTTATCTTCMouse
18 sAGTCCCTGCCCTTTGTACACACGATCCGAGGGCCTCACTA
ActbCTAAGGCCAACCGTGAAAAGACCAGAGGCATACAGGGACAMouse
NppbATCCGTCAGTCGTTTGGGCAGAGTCAGAAACTGGAGTCMouse
G6pdGGCCAACCGTCTGTTCTACCTCCACTATGATGCGGTTCCAGCRat
PgdCGGGTCATACTGCTCGTGAAAGGTCCTGGCATCTTCTTGTCGRat
Nqo1CACTACGATCCGCCCCCAACGCGTGGGCCAATACAATCAGGRat
GclcGTCAAGGACCGGCACAAGGAGAACATCGCCGCCATTCAGTRat
GclmTGCCACCAGATTTGACTGCATTTTCCTGGAAACTTGCCTCAGAGAGRat
GssGAGGTCCGCAAAGAACCCCAGAGCGTGAATGGGGCATACGRat
GsrTCACCCCGATGTATCACGCTGCCCTGAAGCATCTCATCGCRat
Gpx4AGCAACAGCCACGAGTTCCTATCGATGTCCTTGGCTGCGARat
Gsta1ACTTCGATGGCAGGGGGAGAATGGAACATCAAACTCCCATCATTCCRat
Gsta2TTGACGGGATGAAGCTGGCAGTCAGATCTAAAATGCCTTCGGTGTRat
Gstm1CCAAGTGCCTGGACGCCTTCATAGGTGTTGAGAGGTAGCGGCRat
Gstp1CGTCCACGCAGCTTTGAGTGTAACCACCTCCTCCTTCCAGCRat
Txn1AGTAGACGTGGATGACTGCCAAGCACCAGAGAACTCCCCAACRat
Prdx1TCAGATCCCAAGCGCACCATAGCGGCCAACAGGAAGATCARat
Txnrd1AATGCTGGAGAGGTGACGCAGATGTCTCCCCCAGAACGCTRat
Sirt1CAGTGTCATGGTTCCTTTGCCACCGAGGAACTACCTGATMouse
Sirt3GCTGCTTCTGCGGCTCTATACGAAGGACCTTCGACAGACCGTMouse
Sirt4GTGGAAGAATAAGAATGAGCGGAGGCACAAATAACCCCGAGGMouse
Sirt5CCACCGACAGATTCAGGTTTTTCCCGTTAGTGCCCTGCTTTAMouse
Sirt6ATGTCGGTGAATTATGCAGCAGCTGGAGGACTGCCACATTAMouse
Sirt7CAGGTGTCACGCATCCTGAGGCCCGTGTAGACAACCAAGTMouse
CatCCAGCCAGCGACCAGATGAACCTATTGGGTTCCCGCCTCCRat
Sod1AACTGAAGGCGAGCATGGGTTATGCCTCTCTTCATCCGCTGGRat
Sod2GGGGCCATATCAATCACAGCAGAACCTTGGACTCCCACAGACRat
Sod3ACGTTCTTGGGAGAGCTTGTCTGCTAAGTCGACACCGGACRat
ActbGGCTCCTAGCACCATGAAGACAGTGAGGCCAGGATAGAGCRat
Hprt 1CCCTCAGTCCCAGCGTCGTGCGAGCAAGTCTTTCAGTCCTGTCCRat
B2mCCGTGATCTTTCTGGTGCTTGGAGACACGTAGCAGTTGAGGARat
G6pdGTCTTTGCTCGGTGCTTGTCAGCATAGAGGGCCTTACGGAMouse
Nqo1TCTCTGGCCGATTCAGAGTGCCAGACGGTTTCCAGACGTTMouse
GclmATGACCCGAAAGAACTGCTCTGGGTGTGAGCTGGAGTTAAGMouse
GclcACTGAATGGAGGCGATGTTCTTCAGAGGGTCGGATGGTTGGMouse
GssGCACCGACACGTTCTCAATGTAGCACCACCGCATTAGCTGMouse
GsrATGTTGACTGCCTGCTCTGGATCCGTCTGAATGCCCACTTMouse
Gpx4GTACTGCAACAGCTCCGAGTATGCACACGAAACCCCTGTAMouse
Gsta2CCAGGACTCTCACTAGACCGTCCCGGGCATTGAAGTAGTGAMouse
gstm1ATACACCATGGGTGACGCTCTCCATCCAGGTGGTGCTTTCMouse
Gstp1GTCTACGCAGCACTGAATCCGGGAGCTGCCCATACAGACAMouse
Txn1GCGCTCCGCCCTATTTCTATCCTCCTGAAAAGCTTCCTTGCMouse
Prdx1ACTGACAAACATGGTGAAGTGTGTACAAGAGTTTCTTCTGGCTGCMouse
Txnrd1GAATGGACAGTCCCATCCCGAAGCCCACGACACGTTCATCMouse
ActbTAAAACCCGGCGGCGCAGTCATCCATGGCGAACTGGTMouse
Hprt1AGAGCGTTGGGCTTACCTCATGGTTCATCATCGCTAATCACGMouse
B2mACGCCTGCAGAGTTAAGCATTGATCACATGTCTCGATCCCAGMouse
Appendix 1—key resources table
Reagent type (species) or resourceDesignationSource or referenceIdentifiersAdditional information
Strain, strain background (Mus musculus, male, C57BL/6)Sirt2 knockout miceDr. Gius Labrefer to: SIRT2 Maintains Genome Integrity and Suppresses Tumorigenesis through Regulating APC/C Activity.
Strain, strain background (Mus musculus, male, C57BL/6)Sirt2 flox/flox minceDr. Gius Labrefer to: SIRT2 deletion enhances KRAS-induced tumorigenesis in vivo by regulating K147 acetylation status
Strain, strain background (Mus musculus, male, C57BL/6)Nrf2 knockout micethe Jackson LaboratoryRRID:IMSR_JAX:017009
Strain, strain background (Rattus norvegicus domestica, female)Sprague–Dawley ratCharles River
AntibodyRabbit polyclonal SIRT1 antibodySigma07–131WB (1:1000)
AntibodyRabbit polyclonal SIRT2 antibodySigmaS8447WB (1:1000)
AntibodyRabbit mAb SIRT3 antibodyCell Signaling TechnologyRabbit mAb #5490WB (1:1000)
AntibodyRabbit polyclonal anti-HPRT antibodyProteintech150-59-1-APWB (1:5000)
AntibodyMouse monoclonal anti-GAPDH antibodyProteintech60004–1-IgWB (1:10000)
AntibodyRabbit mAb NRF2 antibodyCell Signaling TechnologyRabbit mAb #20733WB (1:1000)
AntibodyRabbit polycloncal NRF2 antibodyAbcamab31163WB (1:1000)
AntibodyHRP-conjugated donkey polyclonal anti-mouse IgG antibodyJackson
ImmunoResearch		715-035-150WB (1:5000)
AntibodyHRP-conjugated donkey polyclonal anti-rabbit IgG antibodyJackson
ImmunoResearch		711-035-152WB (1:5000)
AntibodyRabbit Anti beta Actin antibodyAbcamab8227WB (1:2000)
AntibodyRabbTBP antibodyAbcamab63766WB (1:2000)
AntibodyRabbit mAb SIRT6 antibodyCell Signaling TechnologyRabbit mAb #12486WB (1:1000)
AntibodyMouse Flag-M2 monoclonal antibodySigmaF1804WB: (1:2000); IP(1:xxx)
AntibodyAcetyl Lysine Antibody, AgaroseimmunechemICP0388-2MGIP: 1:10
Chemical compound, drugPropodium IodineSigmaP4170-10MG
Chemical compound, drugHoechst 34432Life Technology62249
Chemical compound, drugCycloheximideSigma1810
Chemical compound, drugParaformaldehydeThermo Fisher ScientificAC416780250
Chemical compound, drugRIPA BufferThermo Fisher Scientific89901
Chemical compound, drugProteaseArrest Protease InhibitorG-Biosciences786–437
Chemical compound, drug10% formalinFisher ScientificFLSF1004
Chemical compound, drugBrdUSigma19–160
Chemical compound, drugvitamin B12SigmaV2876
Chemical compound, drugFBSBio-TechneS11550
Chemical compound, drugpenicillin–streptomycinCytivaSV30010
Chemical compound, drugLipofectamine 2000 Transfection ReagentInvitrogen, Thermo Fisher Scientific11668027
Chemical compound, drugDharmafect transfection reagentHorizon2001–03
Chemical compound, drugAGK2SelleckchemS7577
Chemical compound, drughydrogen peroxideFisher ScientificH324-500
Chemical compound, drugNormal Rabbit IgGSigma12–370
Chemical compound, drugDMSOSigmaD4540
Cell lineH9c2ATCCCRL-1446
OtherDMEMCorning10-013CV
Commercial assay or kitRNA-STAT60TeltestCs-502
Commercial assay or kitDNAse IAmbionAM2222
Commercial assay or kitPerfeCTa SYBR Green FastMixQuanta95074–05 K
Commercial assay or kitqScript cDNA Synthesis KitQuanta95047–500
Commercial assay or kitSuperSignal West Pico PLUS Chemiluminescent SubstratePierce34579
Commercial assay or kitBCA Protein Assay KitPierce23225
Commercial assay or kitNE-PER Nuclear and Cytoplasmic Extraction ReagentsPiercePI78835
Commercial assay or kitTrichrome Stain (Masson) KitSigmaHT15-1KT
Commercial assay or kitProtein A AgaroseRoche11719408001
Commercial assay or kitdihydroethidium (DHE) assayThermo Fisher ScientificD11347
Sequence-based reagentRat Sirt2 siRNAHorizon DiscoveryM-082072-01-0005siGENOME Rat Sirt2 (361532) siRNA
Recombinant DNA reagentWildtype SIRT2 plasmidDr. Gius Labrefer to: SIRT2 Maintains Genome Integrity and Suppresses Tumorigenesis through Regulating APC/C Activity
Software, algorithmGraphPad PrismGraphPadVersion 9
Software, algorithmImageJNIH1.53 c

Data availability

Source data files are provided.

References

    1. Matsushima S
    2. Sadoshima J
    (2015) The role of sirtuins in cardiac disease
    American Journal of Physiology. Heart and Circulatory Physiology 309:H1375–H1389.
    https://doi.org/10.1152/ajpheart.00053.2015

Article and author information

Author details

  1. Xiaoyan Yang

    Feinberg Cardiovascular and Renal Research Institute, Northwestern University School of Medicine, Chicago, United States
    Contribution
    Data curation, Software, Formal analysis, Validation, Visualization, Methodology, Writing – review and editing
    Contributed equally with
    Hsiang-Chun Chang and Yuki Tatekoshi
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-4450-7554

  2. Hsiang-Chun Chang

    Feinberg Cardiovascular and Renal Research Institute, Northwestern University School of Medicine, Chicago, United States
    Contribution
    Data curation, Software, Formal analysis, Validation, Visualization, Methodology, Writing – review and editing
    Contributed equally with
    Xiaoyan Yang and Yuki Tatekoshi
    Competing interests
    No competing interests declared

  3. Yuki Tatekoshi

    Feinberg Cardiovascular and Renal Research Institute, Northwestern University School of Medicine, Chicago, United States
    Contribution
    Data curation, Formal analysis, Validation, Investigation, Visualization, Methodology, Writing – review and editing
    Contributed equally with
    Xiaoyan Yang and Hsiang-Chun Chang
    Competing interests
    No competing interests declared

  4. Amir Mahmoodzadeh

    Feinberg Cardiovascular and Renal Research Institute, Northwestern University School of Medicine, Chicago, United States
    Contribution
    Data curation, Formal analysis, Project administration
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-0523-8152

  5. Maryam Balibegloo

    Feinberg Cardiovascular and Renal Research Institute, Northwestern University School of Medicine, Chicago, United States
    Contribution
    Investigation, Methodology
    Competing interests
    No competing interests declared

  6. Zeinab Najafi

    Feinberg Cardiovascular and Renal Research Institute, Northwestern University School of Medicine, Chicago, United States
    Contribution
    Data curation, Formal analysis
    Competing interests
    No competing interests declared

  7. Rongxue Wu

    Feinberg Cardiovascular and Renal Research Institute, Northwestern University School of Medicine, Chicago, United States
    Contribution
    Investigation, Methodology
    Competing interests
    No competing interests declared

  8. Chunlei Chen

    Feinberg Cardiovascular and Renal Research Institute, Northwestern University School of Medicine, Chicago, United States
    Contribution
    Investigation, Methodology
    Competing interests
    No competing interests declared

  9. Tatsuya Sato

    Feinberg Cardiovascular and Renal Research Institute, Northwestern University School of Medicine, Chicago, United States
    Contribution
    Investigation, Methodology
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-7876-1772

  10. Jason Shapiro

    Feinberg Cardiovascular and Renal Research Institute, Northwestern University School of Medicine, Chicago, United States
    Contribution
    Data curation, Formal analysis, Investigation, Methodology
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-0880-3142

  11. Hossein Ardehali

    Feinberg Cardiovascular and Renal Research Institute, Northwestern University School of Medicine, Chicago, United States
    Contribution
    Conceptualization, Resources, Data curation, Formal analysis, Supervision, Funding acquisition, Investigation, Writing – original draft, Project administration, Writing – review and editing
    For correspondence
    h-ardehali@northwestern.edu
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-7662-0551

Funding

National Institutes of Health (R01 HL140973)

  • Hossein Ardehali

National Institutes of Health (R01 HL138982)

  • Hossein Ardehali

National Institutes of Health (R01 HL140927)

  • Hossein Ardehali

National Institutes of Health (R01 HL155953)

  • Hossein Ardehali

Leducq (Cardiooncology Network)

  • Hossein Ardehali

American Heart Association (14POST20490097)

  • Xiaoyan Yang

American Heart Association (POST000204352)

  • Yuki Tatekoshi

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Acknowledgements

The authors like to thank David Gius and Athanassios Vassilopoulos for helpful discussion and providing mice and reagents. We would also like to thank Mingyang Liu for managing our mouse colony and genotyping the mice used in this study. We thank Chunlei Chen for conducting the animal surgery experiments. The authors also thank Dr. Sathyamangla Prasad from Cleveland Clinic Foundation for providing the human samples to us. XY is supported by the American Heart Association grant 14POST20490097. YT is supported by the American Heart Association grant POST000204352. HA is supported by NIH R01 HL140973, R01 HL138982, R01 HL140927, R01 HL155953, and a grant from Leducq foundation.

Ethics

All animals were maintained and handled in accordance with the Northwestern Animal Care and Use Committee. All animal studies were approved by the Institutional Animal Care and Use Committee at Northwestern University (Chicago, Illinois) and were performed in accordance with guidelines from the National Institutes of Health. The approval number of the animal protocol currently associated with this activity is IS00006808.

Copyright

© 2023, Yang, Chang, Tatekoshi et al.

This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,066
    views
  • 199
    downloads
  • 7
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Xiaoyan Yang
  2. Hsiang-Chun Chang
  3. Yuki Tatekoshi
  4. Amir Mahmoodzadeh
  5. Maryam Balibegloo
  6. Zeinab Najafi
  7. Rongxue Wu
  8. Chunlei Chen
  9. Tatsuya Sato
  10. Jason Shapiro
  11. Hossein Ardehali
(2023)
SIRT2 inhibition protects against cardiac hypertrophy and ischemic injury
eLife 12:e85571.
https://doi.org/10.7554/eLife.85571

Share this article

https://doi.org/10.7554/eLife.85571

Categories and tags

Research organism

Further reading

    1. Medicine

    Cardiology: A new strategy for cardiac protection

    Esmaa Bouhamida, Hina W Chaudhry
    Insight

    It may be possible to treat cardiac hypertrophy and injury by using drugs that inhibit a protein called SIRT2.

    1. Biochemistry and Chemical Biology
    2. Medicine

    Synthesis and biological assessment of chalcone and pyrazoline derivatives as novel inhibitor for ELF3-MED23 interaction

    Soo-Yeon Hwang, Kyung-Hwa Jeon ... Youngjoo Kwon
    Research Article

    HER2 overexpression significantly contributes to the aggressive nature and recurrent patterns observed in various solid tumors, notably gastric cancers. Trastuzumab, HER2-targeting monoclonal antibody drug, has shown considerable clinical success; however, readily emerging drug resistance emphasizes the pressing need for improved interventions in HER2-overexpressing cancers. To address this, we proposed targeting the protein-protein interaction (PPI) between ELF3 and MED23 as an alternative therapeutic approach to trastuzumab. In this study, we synthesized a total of 26 compounds consisting of 10 chalcones, 7 pyrazoline acetyl, and 9 pyrazoline propionyl derivatives, and evaluated their biological activity as potential ELF3-MED23 PPI inhibitors. Upon systematic analysis, candidate compound 10 was selected due to its potency in downregulating reporter gene activity of ERBB2 promoter confirmed by SEAP activity and its effect on HER2 protein and mRNA levels. Compound 10 effectively disrupted the binding interface between the ELF3 TAD domain and the 391–582 amino acid region of MED23, resulting in successful inhibition of the ELF3-MED23 PPI. This intervention led to a substantial reduction in HER2 levels and its downstream signals in the HER2-positive gastric cancer cell line. Subsequently, compound 10 induced significant apoptosis and anti-proliferative effects, demonstrating superior in vitro and in vivo anticancer activity overall. We found that the anticancer activity of compound 10 was not only restricted to trastuzumab-sensitive cases, but was also valid for trastuzumab-refractory clones. This suggests its potential as a viable therapeutic option for trastuzumab-resistant gastric cancers. In summary, compound 10 could be a novel alternative therapeutic strategy for HER2-overexpressing cancers, overcoming the limitations of trastuzumab.

    1. Medicine

    Enhancing bone regeneration and osseointegration using rhPTH(1-34) and dimeric R25CPTH(1-34) in an osteoporotic beagle model

    Jeong-Oh Shin, Jong-Bin Lee ... Jin-Woo Kim
    Research Article

    This study investigates the effects of two parathyroid hormone (PTH) analogs, rhPTH(1-34) and dimeric R25CPTH(1-34), on bone regeneration and osseointegration in a postmenopausal osteoporosis model using beagle dogs. Twelve osteoporotic female beagles were subjected to implant surgeries and assigned to one of three groups: control, rhPTH(1-34), or dimeric R25CPTH(1-34). Bone regeneration and osseointegration were evaluated after 10 weeks using micro-computed tomographic (micro-CT), histological analyses, and serum biochemical assays. Results showed that the rhPTH(1-34) group demonstrated superior improvements in bone mineral density, trabecular architecture, and osseointegration compared to controls, while the dimeric R25CPTH(1-34) group exhibited similar, though slightly less pronounced, anabolic effects. Histological and TRAP assays indicated both PTH analogs significantly enhanced bone regeneration, especially in artificially created bone defects. The findings suggest that both rhPTH(1-34) and dimeric R25CPTH(1-34) hold potential as therapeutic agents for promoting bone regeneration and improving osseointegration around implants in osteoporotic conditions, with implications for their use in bone-related pathologies and reconstructive surgeries.